FHTX
Foghorn Therapeutics Inc.
$4.41
+$0.10(+2.32%)
41
Overall
40
Value
41
Tech
44
Quality
Market Cap
$283.78M
Volume
152.10K
52W Range
$2.95 - $9.70
Target Price
$11.67
Order:
Income Statement
| Metric | Trend | Chart | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|
| REVENUE | |||||||
| Total Revenue | $430.0K | $1.3M | $19.2M | $34.2M | $22.6M | ||
| Total Revenue | $430.0K | $1.3M | $19.2M | $34.2M | $22.6M | ||
| GROSS PROFIT | |||||||
| Gross Profit | $430.0K | $1.3M | $19.2M | $34.2M | $22.6M | ||
| OPERATING EXPENSES | |||||||
| Operating Expenses | $69.0M | $102.1M | $136.4M | $142.1M | $125.3M | ||
| Research & Development | $57.7M | $80.3M | $105.6M | $109.7M | $94.5M | ||
| Research Expense | $57.7M | $80.3M | $105.6M | $109.7M | $94.5M | ||
| Selling, General & Administrative | $11.2M | $21.7M | $30.7M | $32.4M | $28.4M | ||
| General & Administrative Expenses | $11.2M | $21.7M | $30.7M | $32.4M | $28.4M | ||
| Salaries & Wages | $3.0M | $8.4M | $14.3M | $16.2M | $11.9M | ||
| Depreciation & Amortization | $1.3M | $3.2M | $3.3M | $3.5M | $3.1M | ||
| Depreciation & Amortization | $1.3M | $3.2M | $3.3M | $3.5M | $3.1M | ||
| Other Operating Expenses | $8.3M | $10.4M | $10.9M | $10.5M | $11.0M | ||
| OPERATING INCOME | |||||||
| Operating income | $-68.5M | $-100.7M | $-117.1M | $-107.9M | $-102.7M | ||
| EBITDA | $-66.5M | $-96.0M | $-113.8M | $-90.7M | $-83.5M | ||
| NON-OPERATING ITEMS | |||||||
| Interest Expense (Non-Operating) | $979.0K | $1.9M | -- | -- | -- | ||
| Intinc | -- | $59.0K | $5.7M | $10.9M | $11.9M | ||
| Net Non-Operating Interest Income/Expense | $-979.0K | $-1.8M | $5.7M | $10.9M | $11.9M | ||
| Other Income/Expense | $-710.0K | $-1.3M | $2.6M | $-3.2M | $2.4M | ||
| Other Special Charges | $710.0K | $1.3M | $2.6M | -- | -- | ||
| SPECIAL ITEMS | |||||||
| Other Impairment Of Capital Assets | -- | -- | -- | -- | $2.4M | ||
| PRE-TAX INCOME | |||||||
| EBIT | $-67.8M | $-99.4M | $-117.1M | $-94.2M | $-86.6M | ||
| Pre-Tax Income | $-68.8M | $-101.3M | $-108.9M | $-94.2M | $-86.6M | ||
| INCOME TAX | |||||||
| Tax Provision | -- | -- | -- | $4.2M | -- | ||
| NET INCOME | |||||||
| Net Income | $-68.8M | $-101.3M | $-108.9M | $-98.4M | $-86.6M | ||
| Net Income (Continuing Operations) | $-68.8M | $-101.3M | $-108.9M | $-98.4M | $-86.6M | ||
| Net Income (Discontinued Operations) | $-68.8M | $-101.3M | $-108.9M | $-98.4M | $-86.6M | ||
| Net Income (Common Stockholders) | $-68.8M | $-101.3M | $-108.9M | $-98.4M | $-86.6M | ||
| Normalized Income | -- | -- | -- | -- | $-83.4M | ||
| TOTALS | |||||||
| Total Expenses | $69.0M | $102.1M | $136.4M | $142.1M | $125.3M | ||
| SHARE & EPS DATA | |||||||
| Average Shares Outstanding | $11.0M | $37.2M | $41.6M | $42.0M | $54.9M | ||
| Average Shares Outstanding (Diluted) | $11.0M | $37.2M | $41.6M | $42.0M | $54.9M | ||
| Shares Outstanding | $36.8M | $41.4M | $41.8M | $42.6M | $55.6M | ||
| Basic EPS | $-6.23 | $-2.73 | $-2.62 | $-2.34 | $-1.58 | ||
| Basic EPS (Continuing Operations) | $-6.23 | $-2.73 | $-2.62 | $-2.34 | $-1.58 | ||
| Diluted EPS | $-6.23 | $-2.73 | $-2.62 | $-2.34 | $-1.58 | ||
| Diluted EPS (Continuing Operations) | -- | $-2.73 | $-2.62 | $-2.34 | $-1.58 | ||
| OTHER METRICS | |||||||
| Other Gand A | $11.2M | $21.7M | $30.7M | $32.4M | $28.4M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | FHTX | $4.41 | +2.3% | 152.10K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Foghorn Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW